{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:13:08Z","timestamp":1791666788185,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 vaccine dose and compared with those who maintained MTX. Adult RA and PsA patients treated with MTX were recruited and randomly assigned to 3 groups: MTX-maintenance (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200972), MTX-withdrawal for 1 week (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200971) or MTX-withdrawal for 2 weeks (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200973). Specific antibodies to several SARS-CoV-2 antigens and interferon (IFN)-\u03b3 and interleukin (IL)-21 responses were assessed. MTX withdrawal in patients without previous COVID-19 was associated with higher levels of anti-RBD IgG and neutralising antibodies, especially in the 2-week withdrawal group and with higher IFN-\u03b3 secretion upon stimulation with pools of SARS-CoV-2 S peptides. No increment of RA\/PsA relapses was detected across groups. Our data indicate that two-week MTX interruption following COVID-19 vaccination in patients with RA or PsA improves humoral and cellular immune responses.\n                  <\/jats:p>","DOI":"10.1038\/s41541-024-00805-3","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:03:37Z","timestamp":1706619817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis"],"prefix":"10.1038","volume":"9","author":[{"given":"Pedro","family":"Mart\u00ednez-Fleta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-4194","authenticated-orcid":false,"given":"Esther F.","family":"Vicente-Rabaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Triguero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Roy-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Uriarte-Ecenarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Guti\u00e9rrez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Quiroga-Colina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Romero-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Garc\u00eda-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-7941","authenticated-orcid":false,"given":"Gina P.","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas A.","family":"Garc\u00eda-Vadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Llorente-Cubas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1786-7535","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Serra L\u00f3pez-Matencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urzainqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esparcia-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantzazu","family":"Alfranca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortensia","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"S\u00e1nchez-Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-5199","authenticated-orcid":false,"given":"Isidoro","family":"Gonz\u00e1lez-\u00c1lvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park, J. W., Lagniton, P. N. P., Liu, Y. & Xu, R.-H. mRNA vaccines for COVID-19: what, why and how. Int. J. Biol. Sci. 17, 1446\u20131460 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.41619","volume":"73","author":"KM D\u2019Silva","year":"2021","unstructured":"D\u2019Silva, K. M. et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol. 73, 914\u2013920 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"805_CR4","doi-asserted-by":"publisher","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","volume":"60","author":"R Cordtz","year":"2021","unstructured":"Cordtz, R. et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology 60, SI59\u2013SI67 (2021).","journal-title":"Rheumatology"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2020-217984","volume":"79","author":"DD Freites Nu\u00f1ez","year":"2020","unstructured":"Freites Nu\u00f1ez, D. D. et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 1393\u20131399 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2665-9913(22)00227-2","volume":"4","author":"G Figueroa-Parra","year":"2022","unstructured":"Figueroa-Parra, G. et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 4, e765\u2013e774 (2022).","journal-title":"Lancet Rheumatol."},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2665-9913(21)00247-2","volume":"3","author":"F Fagni","year":"2021","unstructured":"Fagni, F. et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 3, 724\u2013760 (2021).","journal-title":"Lancet Rheumatol."},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua, C., Barnetche, T., Combe, B. & Morel, J. Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 66, 1016\u20131026 (2014).","journal-title":"Arthritis Care Res"},{"key":"805_CR9","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","volume":"36","author":"M Van Aalst","year":"2018","unstructured":"Van Aalst, M. et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine 36, 5832\u20135845 (2018).","journal-title":"Vaccine"},{"key":"805_CR10","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/art.42372","volume":"75","author":"JR Curtis","year":"2023","unstructured":"Curtis, J. R. et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 75, E1\u2013E16 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"805_CR11","first-page":"898","volume":"77","author":"JK Park","year":"2018","unstructured":"Park, J. K. et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann. Rheum. Dis. 77, 898\u2013904 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR12","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","volume":"76","author":"JK Park","year":"2017","unstructured":"Park, J. K. et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann. Rheum. Dis. 76, 1559\u20131565 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","volume":"4","author":"TG Skaria","year":"2022","unstructured":"Skaria, T. G. et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatol. 4, e755\u2013e764 (2022).","journal-title":"Lancet Rheumatol."},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2022-002639","volume":"8","author":"E Habermann","year":"2022","unstructured":"Habermann, E. et al. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open 8, 1\u201310 (2022).","journal-title":"RMD Open"},{"key":"805_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","volume":"10","author":"A Abhishek","year":"2022","unstructured":"Abhishek, A. et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir. Med. 10, 840\u2013850 (2022).","journal-title":"Lancet Respir. Med."},{"key":"805_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/annrheumdis-2021-221876","volume":"81","author":"AN Arumahandi de Silva","year":"2022","unstructured":"Arumahandi de Silva, A. N. et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann. Rheum. Dis. 81, 881\u2013888 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","volume":"81","author":"CSR Araujo","year":"2022","unstructured":"Araujo, C. S. R. et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann. Rheum. Dis. 81, 889\u2013897 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.celrep.2015.09.069","volume":"13","author":"G Xin","year":"2015","unstructured":"Xin, G. et al. A critical role of IL-21-induced BATF in sustaining CD8-T-cell-mediated chronic viral control. Cell Rep. 13, 1118\u20131124 (2015).","journal-title":"Cell Rep."},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1077002","volume":"298","author":"K Ozaki","year":"2002","unstructured":"Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630\u20131634 (2002).","journal-title":"Science"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1126\/science.1175194","volume":"324","author":"JS Yi","year":"2009","unstructured":"Yi, J. S., Du, M. & Zajac, A. J. A Vital Role for Interleukin-21. Science 324, 1572\u20131576 (2009).","journal-title":"Science"},{"key":"805_CR21","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","volume":"4","author":"SK Mahil","year":"2022","unstructured":"Mahil, S. K. et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 4, e42\u2013e52 (2022).","journal-title":"Lancet Rheumatol."},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYBin Lee","year":"2022","unstructured":"Lee, A. R. Y. Bin et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 376, e068632 (2022).","journal-title":"BMJ"},{"key":"805_CR23","first-page":"1","volume":"0","author":"F Kartnig","year":"2022","unstructured":"Kartnig, F. et al. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann. Rheum. Dis. 0, 1\u20139 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR24","doi-asserted-by":"publisher","first-page":"e002293","DOI":"10.1136\/rmdopen-2022-002293","volume":"8","author":"I Andreica","year":"2022","unstructured":"Andreica, I. et al. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination. RMD Open 8, e002293 (2022).","journal-title":"RMD Open"},{"key":"805_CR25","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","volume":"80","author":"S Bugatti","year":"2021","unstructured":"Bugatti, S., De Stefano, L., Balduzzi, S., Greco, M. & Luvaro, T. Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA\u2019s adverse event reporting system. Ann. Rheum. Dis. 80, 1635\u20131638 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR26","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","volume":"4","author":"L Wieske","year":"2022","unstructured":"Wieske, L. et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 4, e338\u2013e350 (2022).","journal-title":"Lancet Rheumatol."},{"key":"805_CR27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","volume":"80","author":"RH Haberman","year":"2021","unstructured":"Haberman, R. H. et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann. Rheum. Dis. 80, 1339\u20131344 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2022-002203","volume":"8","author":"AJ Laster","year":"2022","unstructured":"Laster, A. J. et al. Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)? RMD Open 8, 1\u20134 (2022).","journal-title":"RMD Open"},{"key":"805_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19095-7","volume":"12","author":"BT Montague","year":"2022","unstructured":"Montague, B. T. et al. Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders. Sci. Rep. 12, 14932 (2022).","journal-title":"Sci. Rep."},{"key":"805_CR30","doi-asserted-by":"publisher","first-page":"103888","DOI":"10.1016\/j.ebiom.2022.103888","volume":"77","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero, A. et al. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in na\u00efve and previously COVID-19-infected individuals. eBioMedicine 77, 103888 (2022).","journal-title":"eBioMedicine"},{"key":"805_CR31","doi-asserted-by":"publisher","first-page":"917905","DOI":"10.3389\/fimmu.2022.917905","volume":"13","author":"T Adjobimey","year":"2022","unstructured":"Adjobimey, T. et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm\u2019s COVID-19 vaccines. Front. Immunol. 13, 917905 (2022).","journal-title":"Front. Immunol."},{"key":"805_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00296-022-05123-2","volume":"42","author":"M Feuchtenberger","year":"2022","unstructured":"Feuchtenberger, M., Kovacs, M. S., Eder, A., Nigg, A. & Sch\u00e4fer, A. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Rheumatol. Int. 42, 959\u2013966 (2022).","journal-title":"Rheumatol. Int."},{"key":"805_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijid.2022.04.027","volume":"121","author":"L Petrone","year":"2022","unstructured":"Petrone, L. et al. Humoral and cellular responses to spike of \u03b4 SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. Int. J. Infect. Dis. 121, 24\u201330 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"805_CR34","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.3390\/ijms22179521","volume":"22","author":"H Asao","year":"2021","unstructured":"Asao, H. Interleukin-21 in Viral Infections. Int. J. Mol. Sci. 22, 9521 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"805_CR35","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen, J. & van Riel, P. L. C. M. The Disease Activity Score and the EULAR response criteria. Clin. Exp. Rheumatol. 23, S93\u20139 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"805_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR37","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"805_CR38","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","volume":"72","author":"A Van Der Maas","year":"2013","unstructured":"Van Der Maas, A. et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: An OMERACT cohort validation study. Ann. Rheum. Dis. 72, 1800\u20131805 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"805_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. B. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"805_CR40","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.4049\/jimmunol.172.9.5154","volume":"172","author":"J P\u00e8ne","year":"2004","unstructured":"P\u00e8ne, J. et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. 172, 5154\u20135157 (2004).","journal-title":"J. Immunol."},{"key":"805_CR41","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.4049\/jimmunol.175.12.7867","volume":"175","author":"R Ettinger","year":"2005","unstructured":"Ettinger, R. et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175, 7867\u20137879 (2005).","journal-title":"J. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00805-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00805-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00805-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T16:26:24Z","timestamp":1706631984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00805-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00805-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C. has received consultation fees in company-sponsored speaker\u2019s bureau from Amgen, BMS, Eli-Lilly, MSD, Roche, Sanofi and UCB. S. Casta\u00f1eda is assistant professor of the c\u00e1tedra UAM-Roche, EPID-Future, Universidad Aut\u00f3noma de Madrid (UAM), Madrid, Spain. I.G.-A. reports grants from Instituto de Salud Carlos III, during the course of the study; personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The rest of the authors do not declare conflicts of interest in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}